Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.

Therapeutics

Catalym

Catalym's headquarters in Munich, Germany

Scott Clarke

Vanja Radulovic

Thorsten Ross

Julia Kruschel

Bernhard Rössler

María Cecilia González

Jonathan Tobin

Gabriele Zacke

Sabrina Genßler

Eugen Leo

Anne Burger

Hans van Eenennaam

John Haurum

Marc Lohrmann

Rogier Rooswinkel

Nathalie Weitemeyer

Oskar Slotboom

Marianne Uteng

Andreas Wallnöfer

Roy Baynes

The Board Members at Catalym provide strategic guidance, oversight, and governance to ensure the company effectively develops targeted antibodies against placental factors overexpressed in various tumor types. They make high-level decisions, support executive management, and shape the long-term vision and mission of the company.

Board Members

The Scientific Research and Bioanalytics team at Catalym is responsible for investigating and validating the role of placental factors in tumor biology. They develop and analyze antibodies targeting these factors, using state-of-the-art bioanalytical techniques to ensure efficacy and safety in various cancer therapies.

Scientific Research and Bioanalytics

The Leadership Team at Catalym spearheads the company's strategic direction and operational excellence, overseeing aspects from preclinical research and regulatory affairs to clinical operations and financial management. This cohesive unit ensures the effective development and translation of innovative antibody therapies targeting placental factors in various tumors, driving the company's mission forward.

Leadership Team

Catalym

Org chart

Board & advisors

Teams

Board Members

Scientific Research and Bioanalytics

Leadership Team

Offices

Catalym

Org chart

Board & advisors

Teams

Board Members

Scientific Research and Bioanalytics

Leadership Team

Offices

Related companies